The efficacy of flumazenil in subclinical to mild hepatic encephalopathic ambulatory patients | Zendy

Mehmet Dursun | Zendy; Mustafa Çalışkan | Zendy; Fikri Canoruç | Zendy; Ufuk Aluçlu | Zendy; Naime Canoruç | Zendy; Alpaslan Tuzcu | Zendy; Şerif Yılmaz | Zendy; Abdurrahman Işıkdoğan | Zendy; Melikşah Ertem | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The efficacy of flumazenil in subclinical to mild hepatic encephalopathic ambulatory patients

Author(s) -

Mehmet Dursun,

Mustafa Çalışkan,

Fikri Canoruç,

Ufuk Aluçlu,

Naime Canoruç,

Alpaslan Tuzcu,

Şerif Yılmaz,

Abdurrahman Işıkdoğan,

Melikşah Ertem

Publication year - 2003

Publication title -

schweizerische medizinische wochenschrift

Language(s) - English

Resource type - Journals

ISSN - 0036-7672

DOI - 10.4414/smw.2003.10107

Subject(s) - medicine , flumazenil , hepatic encephalopathy , encephalopathy , cirrhosis , fulminant hepatic failure , anesthesia , placebo , gastroenterology , benzodiazepine , liver transplantation , transplantation , pathology , receptor , alternative medicine

Hepatic encephalopathy (HE) is a neuropsychiatric syndrome associated with fulminant hepatic failure and chronic liver disease. Its pathogenesis is unclear. One of the factors implicated is enhanced GABA-ergic tone, which is probably related to increased concentrations of cerebral benzodiazepine (BNZ). In the present study, we tested flumazenil, a cerebral BNZ antagonist, in cirrhosis patients with hepatic encephalopathy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research